IP Library Granted Patent US 6,919,091
Granted Patent B2
US 6,919,091 · App. 10/095,680 · Granted Jul 19, 2005

Compositions and methods for drug delivery using pH sensitive molecules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,919,091
App. No.
10/095,680
Granted
Jul 19, 2005
Kind
B2
Abstract

An polyampholyte is utilized in a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The complex can be formed with an appropriate amount of positive and/or negative charge such that the resulting complex can be delivered to the extravascular space and may be further delivered to a cell.

Claims (19)

1. The process for delivery of a polyion to a cell, comprising:

a) forming a complex of labile polyampholyte and polyion; and,

b) delivering the complex into a cell.

2. The process of claim 1 wherein the labile bond is a pH labile bond.

3. The process of claim 2 wherin the pH-labile bond is selected from the group consisting of acetal, ketal, silazane, silyl ether, ortho ester, enol ether, enol ester, imine, amidine, imidate ester, substructure of citraconic anhydride, and substructure of maleic anhydride.

4. The process of claim 1 wherein the polyampholyte comprises one or more polycations selected from the group consisting of poly-L-lysine, poly-D-lysine, poly-L,D-lysine, polyethylenimine, polyallylamine, poly-L-ornithine, poly-D-ornithine, poly-L,D-ornithine, polyvinylamine, natural cationic proteins, synthetic cationic proteins, synthetic cationic peptides and synthetic polymers.

5. The process of claim 4 wherein the synthetic polymers consist of monomers with amines selected from the group consisting of alkylamine, aryl amine, aralkylamine, imidazole, pyridine, and piperazine, pyrazine, pyrimidine, oxazoline, and oxazole.

6. The process of claim 1 wherin the polyampholyte comprises one or more polyanions selected from the group consisting of to poly-L-aspartic acid, poly-D-aspartic acid, poly-L,D-aspartic acid, polyacrylic acid, poly-L-glutamic acid, poly-D-glutamic acid, poly-L,D-glutamic acid, succinylated poly-L-lysine, succinylated poly-D-lysine, succinylated poly-L,D-lysine, succinylated polyethylenimine, succinylated polyallylamine, succinylated poly-L-ornithine, succinylated poly-D-ornithine, succinylated poly-L,D-ornithine, succinylated polyvinylamine, polymethacrylic acid, dextran sulfate, heparin, hyaluronic acid, DNA, RNA, natural anionic proteins, synthetic anionic proteins, synthetic anionic peptides, and synthetic polymers contining monomers in which an amine has been reacted with a substructure of citraconic anhydride and/or substructure of maleic anhydride.

7. The process of claim 1 wherein the polyampholyte contains a functional group.

8. The process of claim 7 wherein the functional group on the polyampholyte undergoes a chemical reaction.

9. The process for delivery of a polyion to a cell, comprising:

a) forming a complex of a polyion and a polyampholyte having a pH labile bond; and,

b) delivering the complex into a cell.

10. The process of claim 9 wherein the pH-labile bond is selected from the group consisting of acetal, ketal, silazane, silyl ether, ortho ester, enol ether, enol ester, imine, amidine, imidate ester, substructure of citraconic anhydride, and substructure of maleic anhydride.

11. The process of claim 9 wherein the polyampholyte comprises one or more polycations selected from the group of poly-L-lysine, poly-D-lysine, poly-L,D-lysine, polyethylenimine, polyallylamine, poly-L-ornithine, poly-D-ornithine, poly-L,D-ornithine, polyvinylamine, natural cationic proteins, synthetic cationic proteins, synthetic cationic peptides and synthetic polymers.

12. The process of claim 11 wherein the synthetic polymers contain monomers with amines selected from the group consisting of alkylamine, aryl amine, aralkylamine, imidazole, pyridine, and piperazine, pyrazine, pyrimidine, oxazoline, oxazole.

13. The process of claim 9 wherin the polyampholyte comprises one or more polyanions selected from the group consisting of poly-L-aspartic acid, poly-D-aspartic acid, poly-L,D-aspartic acid, polyacrylic acid, poly-L-glutamic acid, poly-D-glutamic acid, poly-L,D-glutamic acid, succinylated poly-L-lysine, succinylated poly-D-lysine, succinylated poly-L,D-lysine, succinylated polyethylenimine, succinylated polyallylamine, succinylated poly-L-ornithine, succinylated poly-D-ornithine, succinylated poly-L,D-ornithine, succinylated polyvinylamine, polymethacrylic acid, dextran sulfate, heparin, hyaluronic acid, DNA, RNA, natural anionic proteins, synthetic anionic proteins, synthetic anionic peptides, and synthetic polymers contining monomers in which an amine has been reacted with a substructure of citraconic anhydride and/or substructure of maleic anhydride.

14. The process of claim 9 wherein the polyampholyte contains a functional group.

15. The process of claim 14 wherein the functional group on the polyapmpholyte undergoes a chemical reaction.

Assignments (1)
CHANGE OF NAME Recorded Feb 26, 2014
From: ROCHE MADISON INC.
To: ARROWHEAD MADISON INC.
Reel/Frame 032302/0843 →